Featured Research

from universities, journals, and other organizations

New Insights Into Thalidomide-birth Defect Episode

Date:
November 11, 2008
Source:
American Chemical Society
Summary:
Scientists in Germany have discovered why the medication thalidomide appeared safe in animal tests before going on the market 50 years ago, only to cause perhaps the most extensive outbreak of drug-induced birth defects in medical history.

Scientists in Germany have discovered why the medication thalidomide appeared safe in animal tests before going on the market 50 years ago, only to cause perhaps the most extensive outbreak of drug-induced birth defects in medical history.

Their study is scheduled for the December 1 edition of ACS' Molecular Pharmaceutics, a bimonthly journal.

Jurgen Knobloch, Ulrich Ruther and colleagues note that more than 10,000 children were born with severe birth defects after drug regulators in Europe approved the medication for treating nausea and vomiting in pregnant women.

The drug, never approved for that use in the United States, is available for certain conditions, including multiple myeloma and leprosy. The birth defects outbreak puzzled scientists because pre-marketing tests in lab mice and rats showed no sign of a birth defect risk.

The researchers point out that those animals proved to be resistant to thalidomide's adverse effects, and in the new study they describe discovery of the biochemical basis for that resistance. It involves a key difference between human embryonic cells and those of mice. They found in mice cells advanced antioxidant defenses compared to those in humans and other thalidomide-susceptible species.

Therefore, thalidomide is not able to induce the generation of large quantities of damaging free radicals called superoxides in mouse embryonic cells as it does in human embryonic cells (where subsequent cell death is believed to be responsible for birth defects.)


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jόrgen Knobloch, Kerstin Reimann, Lars-Oliver Klotz, and Ulrich Rόther. Thalidomide Resistance Is Based on the Capacity of the Glutathione-Dependent Antioxidant Defense. Mol. Pharmaceutics, Published online: October 22, 2008 DOI: 10.1021/mp8001232

Cite This Page:

American Chemical Society. "New Insights Into Thalidomide-birth Defect Episode." ScienceDaily. ScienceDaily, 11 November 2008. <www.sciencedaily.com/releases/2008/11/081110181711.htm>.
American Chemical Society. (2008, November 11). New Insights Into Thalidomide-birth Defect Episode. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2008/11/081110181711.htm
American Chemical Society. "New Insights Into Thalidomide-birth Defect Episode." ScienceDaily. www.sciencedaily.com/releases/2008/11/081110181711.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) — A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) — Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) — California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) — The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins